AI Summary
The content discusses a Phase 3 trial called VANCE, which examines the use of a combination of gemcitabine, carboplatin, and Epstein-Barr virus-specific autologous cytotoxic T lymphocytes in patients with recurrent or metastatic nasopharyngeal carcinoma (R/M NPC). The study aims to determine if this chemo-immunotherapy strategy is more effective and improves quality of life compared to conventional chemotherapy treatment.
Epstein-Barr virus-specific cytotoxic T lymphocyte (EBV-CTL) is an autologous adoptive T cell immunotherapy generated from the blood of individuals and manufactured without genetic modification. In a previous Phase 2 trial of locally recurrent or metastatic nasopharyngeal cancer (R/M NPC) patients, first-line gemcitabine and carboplatin (GC) and EBV-CTL combination demonstrated objective anti-tumor EBV-CTL activity and a favorable safety profile. The present study explored whether this combined first-line chemo-immunotherapy strategy would produce superior clinical efficacy and better quality of life compared to conventional chemotherapy treatment.